Drug Name |
Azilsartan kamedoxomil |
Drug ID |
BADD_D00201 |
Description |
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011.[A7354] Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension.[A232863]
Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease,[A7354] early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.[L32918] Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.[A232863] |
Indications and Usage |
Treatment of hypertension (alone or as an adjunct). |
Marketing Status |
Not Available |
ATC Code |
C09CA09 |
DrugBank ID |
DB08822
|
KEGG ID |
D08865
|
MeSH ID |
C557413
|
PubChem ID |
23699544
|
TTD Drug ID |
D0A2RA
|
NDC Product Code |
69037-0001; 60631-080; 65085-0074; 60631-040; 59651-498; 11532-2003; 14501-0094; 11532-2002 |
Synonyms |
azilsartan medoxomil | TAK 491 | TAK491 | TAK-491 |